04:49 PM EDT, 09/30/2025 (MT Newswires) -- Matthew K Fust, Director, on September 26, 2025, sold 16,000 shares in Crinetics Pharmaceuticals ( CRNX ) for $716,000. Following the Form 4 filing with the SEC, Fust has control over a total of 22,836 common shares of the company, with 22,836 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1658247/000165824725000010/xslF345X05/wk-form4_1759264890.xml